![](/images/graphics-bg.png)
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure
Joint Authors
Ye, Hanhui
Huang, Zuxiong
Wang, Ning
Huang, Shuiwen
Chen, Yi
Yang, Shida
Gan, Qiaorong
Liu, Baorong
Pan, Chen
Source
Gastroenterology Research and Practice
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-05-02
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Aims.
Soluble urokinase plasminogen activator receptor (suPAR) reflects the immune activation in circumstances of inflammation and infection.
It has been considered as a risk biomarker associated with poor outcome in various low-grade inflammation and infectious diseases.
The study is aimed at investigating whether suPAR has a predictive value with short-term survival in patients with hepatitis B-related acute-on-chronic liver failure (HB-ACLF).
Methods.
Serum suPAR expression was compared among patients with different states of chronic hepatitis B virus infection.
Sixty HB-ACLF patients were recruited as the training cohort and followed up for 90 days.
Serum suPAR level and the clinical relevance with short-term outcome were investigated.
The temporal dynamics of suPAR were evaluated in 50 HB-ACLF patients with available serum sequentially at baseline, week 2 and week 4.
Another 167 HB-ACLF patients were enrolled to validate the predictive value of suPAR with respect to the prognosis.
Results.
Serum suPAR level was significantly increased in HB-ACLF patients compared to non-ACLF patients.
In the training set of HB-ACLF, we observed higher suPAR level, INR, MELD score, and more complications in nonsurvivors than survivors.
Longitudinal analysis revealed an increased trend of suPAR level in nonsurvivors during week 0 to week 4 and the modest decline in survivors.
It showed that the synchronous suPAR level was higher in nonsurvivors at all indicated time points.
Elevated suPAR level at baseline was identified as a strong predictor of a 90-day mortality of HB-ACLF patients.
It was confirmed suPAR>16.26 ng/ml had a positive predictive value of 72.22% and a negative predictive value of 77.88% for poor outcome in the validation cohort.
Conclusions.
Serum suPAR level increases significantly in HB-ACLF patients and associated with a 90-day mortality.
It suggests that suPAR might be a potential biomarker to predict the prognosis of HB-ACLF patients.
American Psychological Association (APA)
Huang, Zuxiong& Wang, Ning& Huang, Shuiwen& Chen, Yi& Yang, Shida& Gan, Qiaorong…[et al.]. 2019. Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Gastroenterology Research and Practice،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1155095
Modern Language Association (MLA)
Huang, Zuxiong…[et al.]. Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Gastroenterology Research and Practice No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1155095
American Medical Association (AMA)
Huang, Zuxiong& Wang, Ning& Huang, Shuiwen& Chen, Yi& Yang, Shida& Gan, Qiaorong…[et al.]. Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Gastroenterology Research and Practice. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1155095
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1155095